INT85923

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.67
First Reported 1999
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 25
Total Number 25
Disease Relevance 7.03
Pain Relevance 6.53

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (CREM) signal transduction (CREM) nucleus (CREM)
DNA binding (CREM)
Anatomy Link Frequency
T cells 7
PC-3 1
PVN 1
CREM (Homo sapiens)
Pain Link Frequency Relevance Heat
abatacept 119 100.00 Very High Very High Very High
Morphine 49 98.66 Very High Very High Very High
cytokine 6 98.44 Very High Very High Very High
cINOD 28 98.32 Very High Very High Very High
Inflammation 15 98.26 Very High Very High Very High
Lamotrigine 10 97.72 Very High Very High Very High
cva 19 96.04 Very High Very High Very High
methotrexate 28 95.72 Very High Very High Very High
Enkephalin 3 92.64 High High
COX-2 inhibitor 1 91.92 High High
Disease Link Frequency Relevance Heat
Ulcers 47 100.00 Very High Very High Very High
Hypoxia 29 100.00 Very High Very High Very High
Repression 1 98.88 Very High Very High Very High
Apoptosis 9 98.72 Very High Very High Very High
Disease Progression 8 98.36 Very High Very High Very High
INFLAMMATION 24 98.26 Very High Very High Very High
Cv General 3 Under Development 19 96.04 Very High Very High Very High
Myocardial Infarction 2 95.16 Very High Very High Very High
Diabetes Mellitus 5 94.40 High High
Stroke 7 94.24 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
PhosphoCREB is downregulated and CREM/ICER is upregulated in the PVN by muscimol, suggesting that the regulation of these transcription factors may underlie the inhibitory effect of muscimol on target genes in the PVN.
Positive_regulation (upregulated) of CREM in PVN
1) Confidence 0.67 Published 1999 Journal J. Mol. Neurosci. Section Abstract Doc Link 10636469 Disease Relevance 0 Pain Relevance 0.07
Candidate transcription factors regulating the proenkephalin gene in opposite directions are cAMP-response-element-binding protein (CREB) (when phosphorylated, a positive regulator) and cAMP-responsive modulatory inducible cAMP early repressor (CREM/ICER) (a negative regulator).
Positive_regulation (inducible) of CREM
2) Confidence 0.49 Published 1999 Journal J. Mol. Neurosci. Section Abstract Doc Link 10636469 Disease Relevance 0 Pain Relevance 0.09
The ICER for a specific subgroup was dependent on: i) the differences between the whole program costs, ii) the differences in the number of recipients of additional treatment and consequential costs and iii) differences in the number of new leprosy cases found in the sub-group [6], [7].


Positive_regulation (dependent) of ICER associated with mycobacterium infection
3) Confidence 0.44 Published 2010 Journal PLoS Neglected Tropical Diseases Section Body Doc Link PMC2970532 Disease Relevance 0.33 Pain Relevance 0
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (up-regulation) of ICER in T cells associated with morphine
4) Confidence 0.44 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.48
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (up-regulation) of early repressor in T cells associated with morphine
5) Confidence 0.38 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.48
ICER was calculated as follows*:
Positive_regulation (calculated) of ICER
6) Confidence 0.32 Published 2009 Journal Psychiatry Investigation Section Body Doc Link PMC2796067 Disease Relevance 0.16 Pain Relevance 0
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (inducible) of ICER in T cells associated with morphine
7) Confidence 0.31 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.48
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (up-regulation) of ICER in T cells associated with morphine
8) Confidence 0.31 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.48
Compared with current medication only, Messori et al.25 found that adjunctive LTG cost an additional US$ 1,612,370 for a cohort of 100 patients over the patients' lifetimes, gained 39 QALYs, and calculated an ICER of US$ 41,343 per QALY.
Positive_regulation (calculated) of ICER associated with lamotrigine
9) Confidence 0.28 Published 2009 Journal Psychiatry Investigation Section Body Doc Link PMC2796067 Disease Relevance 0.27 Pain Relevance 0.33
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (up-regulation) of early repressor in T cells associated with morphine
10) Confidence 0.27 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.48
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (inducible) of early repressor in T cells associated with morphine
11) Confidence 0.27 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.47
Although the system has been validated using Galpha(s)-coupled receptor-mediated activation of a cAMP response element, the method can be applied to other types of targets and/or transcriptional response elements.
Positive_regulation (activation) of cAMP response element
12) Confidence 0.26 Published 2000 Journal J Biomol Screen Section Abstract Doc Link 11080697 Disease Relevance 0 Pain Relevance 0.08
Herein, we show that chronic morphine treatment results in an increase in cAMP levels with a concurrent up-regulation of the cAMP inducible repressor inducible cAMP early repressor (ICER)/cAMP response element modulator (CREM) and down-regulation of p-cAMP-response element-binding protein (CREB) in activated T cells.
Positive_regulation (up-regulation) of CREM in T cells associated with morphine
13) Confidence 0.25 Published 2007 Journal J. Biol. Chem. Section Abstract Doc Link 17227776 Disease Relevance 0 Pain Relevance 0.49
Our main findings were: 1) the base model incremental cost-effectiveness ratio (ICER) for celecoxib versus nsNSAIDs was $31,097 per QALY; 2) the ICER per QALY was $19,309 for a model in which UGI ulcer and ulcer complication event risks increased with advancing age; 3) the ICER per QALY was $17,120 in sensitivity analyses combining serious CV thromboembolic event (myocardial infarction, stroke, CV death) risks with base model assumptions.


Positive_regulation (increased) of ICER associated with stroke, ulcers, cva, death and myocardial infarction
14) Confidence 0.20 Published 2007 Journal BMC Gastroenterol Section Abstract Doc Link PMC1925103 Disease Relevance 0.88 Pain Relevance 0.31
The ICER, which was derived from both results, was 3,421,394 KRW per QALY (2,895.80 USD per QALY) (Table 6).
Positive_regulation (derived) of ICER
15) Confidence 0.17 Published 2010 Journal BMC Complement Altern Med Section Body Doc Link PMC3009613 Disease Relevance 0.40 Pain Relevance 0.24
The promoter has two parts, the [-247/+20] fragment of the human type IIA secreted phospholipase A2 gene promoter, which is stimulated by the pro-inflammatory cytokine interleukin-1beta (IL-1beta), and a double peroxisome proliferator-activated receptor response element that is activated by some eicosanoids and by non-steroidal anti-inflammatory drugs (NSAIDs).
Positive_regulation (activated) of receptor response element associated with inflammation, cinod and cytokine
16) Confidence 0.17 Published 2002 Journal FEBS Lett. Section Abstract Doc Link 11997019 Disease Relevance 0.45 Pain Relevance 0.50
ET-18-O-CH3 enhanced the transcriptional activities of cyclic AMP response element which is a key regulator of COX-2 expression. 15-Deoxy-Delta(12,14) prostaglandin J2 is, an endogenous ligand for peroxisome proliferator-activated receptor gamma (PPARgamma), has been known to possess proapoptotic potential in diverse cell types.
Positive_regulation (enhanced) of cyclic AMP response element
17) Confidence 0.10 Published 2005 Journal FEBS Lett. Section Abstract Doc Link 16253239 Disease Relevance 0.60 Pain Relevance 0.12
The ICER for abatacept increased to around £70000 if it was assumed that disease progression was 0.012 with conventional DMARDs and 0.009 with abatacept.


Positive_regulation (increased) of ICER associated with abatacept and disease progression
18) Confidence 0.09 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012435 Disease Relevance 0.57 Pain Relevance 1.04
From the NHS perspective, the inclusion of a repeat dose results in an ICER of £24,511/QALY.
Positive_regulation (results) of ICER
19) Confidence 0.07 Published 2010 Journal Cost Eff Resour Alloc Section Body Doc Link PMC2881001 Disease Relevance 0 Pain Relevance 0
The ICER increased rapidly with small differences in the quality of life after conversion of HRA to THA compared to primary THA for men age less than age 55, men age 55 to 64, and women less than age 55.
Positive_regulation (increased) of ICER
20) Confidence 0.07 Published 2010 Journal Clin Orthop Relat Res Section Body Doc Link PMC2914258 Disease Relevance 0.18 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox